Safety of high-dose dual therapy for <i>Helicobacter pylori</i> eradication in patients with varying degrees of metabolic associated fatty liver disease.

At treatment completion, ALT and AST levels showed an increasing trend in patients with mild and moderate fatty liver but a decreasing trend in patients with severe fatty liver; however, none of the differences were statistically significant ( p > 0.05).

also in 47,180 other papers